Compare CNXN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | URGN |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1997 | 2016 |
| Metric | CNXN | URGN |
|---|---|---|
| Price | $80.79 | $47.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.29 |
| AVG Volume (30 Days) | 142.7K | ★ 795.1K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | $6.24 | $129.09 |
| Revenue Next Year | $4.39 | $70.96 |
| P/E Ratio | $41.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.97 | $15.86 |
| 52 Week High | $88.31 | $48.19 |
| Indicator | CNXN | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 67.57 |
| Support Level | $56.57 | $18.23 |
| Resistance Level | $88.31 | N/A |
| Average True Range (ATR) | 3.13 | 2.39 |
| MACD | -0.48 | 0.35 |
| Stochastic Oscillator | 14.47 | 86.58 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.